Aldeyra Therapeutics Inc (STU:137)
€ 4.654 -0.037 (-0.79%) Market Cap: 276.29 Mil Enterprise Value: 184.32 Mil PE Ratio: 0 PB Ratio: 3.43 GF Score: 39/100

Aldeyra Therapeutics Inc TRANQUILITY-2 Top-Line Data Results Call Transcript

Jun 08, 2022 / 12:00PM GMT
Release Date Price: €3.39 (-0.29%)
Operator

Good morning, and welcome to the Aldeyra Therapeutics conference call. My name is Bailey, and I'll be the moderator for today's call. (Operator Instructions)

I would now like to hand the conference over to Bruce Greenberg, Vice President of Finance, Interim Chief Financial Officer and Treasurer. Thank you. Sir, please go ahead.

Bruce Greenberg
Aldeyra Therapeutics, Inc. - VP of Finance, Interim CFO & Treasurer

Thank you, and good morning, everyone. With me is Dr. Todd Brady, President and Chief Executive Officer of Aldeyra. This morning, we issued a press release reporting top line results for the Phase III TRANQUILITY-2 clinical trial of our investigational new drug candidate, reproxalap, in patients with dry eye disease. A copy of the press release is available on the Investors & Media section of our website, www.aldeyra.com. The press release should be read and considered in conjunction with the slides presented and prepared comments made on today's call.

Please turn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot